DDInter557 DDInter112
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Aprepitant
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Aprepitant
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is palliated by {v} (Compound) Aprepitant
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aprepitant
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Fosaprepitant
Fosaprepitant {u} (Compound) resembles {v} (Compound) Aprepitant
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Depressed level of consciousness
Depressed level of consciousness {u} (Side Effect) is caused by {v} (Compound) Citalopram
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aprepitant
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Aprepitant
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aprepitant
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aprepitant (Compound)
Dihydroergotamine (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Aprepitant (Compound)
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is palliated by Aprepitant (Compound)
Dihydroergotamine (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Dihydroergotamine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Fosaprepitant (Compound) and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Dihydroergotamine (Compound) causes Depressed level of consciousness (Side Effect) and Depressed level of consciousness (Side Effect) is caused by Citalopram (Compound) and Citalopram may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Aprepitant